Markets
Camp4 Therapeutics CSO Daniel Tardiff Sells $8,272 in Stock: What Insider Activity Signals for Biotech Investors
Camp4 Therapeutics Chief Scientific Officer Daniel Tardiff has sold $8,272 worth of common stock, a move that — while modest in dollar terms — carries meaningful informational weight for investors tracking insider sentiment in the clinical-stage RNA medicine space.